Dr James O’Mahony is leading this Health Research Board Emerging
Investigator Award (EIA) which contains three principal components. The first addresses the
theoretical and empirical basis for the cost-effectiveness threshold
used to determine if an intervention represents good value for money.
The second examines common methodological problems in
Infection with Human Papillomavirus (HPV) can lead to development of cervical cancer. For this reason HPV now plays an important role in cervical cancer prevention. For example, HPV vaccination programmes are established in several countries worldwide, including Ireland, where a national school based HPV vaccination programme began in 2010.
Achieving high cervical screening coverage is important both for the population and individual women. However older women in Ireland are less likely to engage with cervical screening. The aims of the project are (i) to understand non-participation in cervical cancer screening among older women and (ii) to explore women’s present level of understanding of cervical screening in Ireland.
The research we propose in SYSTEMCERV adopts a systems biology approach to address the need for specific biomarkers to aid objective CIN lesion grading, to identify true high grade cervical disease, and to increase the specificity and PPV of disease detection.
Cancer accounts for nearly one-quarter of deaths in the developed world, exceeded only by heart diseases. Early diagnosis through cancer screening programs is one of the key methods facilitated in cancer prevention as it has the:
Many common diseases currently require that samples be sent to remote labs for diagnosis. This is costly and takes time, increasing patient anxiety and delaying the start of treatment. MicroActive will make it feasible to carry out automatic, accurate diagnosis at the local doctor's office.